Urinary Incontinence Treatment Devices Market

Executive Summary

Urinary Incontinence Treatment Devices Market was valued at US $692.02 million in 2021 and is projected to grow at 6.07% CAGR over the forecast period to reach US $985.66 million by 2027. Urinary Incontinence Treatment Devices Market represented US $76.96 million opportunity over 2019-2021 and estimated to create US $293.64 million opportunity in 2027 over 2021.

Urinary Incontinence Treatment Devices from Consainsights analyses the Urinary Incontinence Treatment Devices Market in the Life Sciences industry over the forecast period to 2027.

Urinary Incontinence Treatment Devices research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Urinary Incontinence Treatment Devices segmentation includes Product, End-User and Geography.

Based on the Product, the Urinary Incontinence Treatment Devices analysis covers Urethral Slings, Electrical Stimulation Devices, Artificial Urinary Sphincters, Catheters and Others.

In Product segment, Urethral Slings segment has highest cagr growth of 5.38%.

Based on the End-User, the Urinary Incontinence Treatment Devices analysis covers Hospitals, Ambulatory Surgical Centres, Other End-Users.

In End-User segment, Other End-Users segment has highest cagr growth of 5.38%.

Based on the region, the Urinary Incontinence Treatment Devices analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Boston Scientific Corporation, Becton, Dickinson and Company, Colopast AS., Promedon Group, A.M.I. GmbH, Johnson & Johnson, Zephyr Surgical Implants, Medtronic PLC, Caldera Medical Inc, Hollister Incorporated, Nipro Corporation, Karl Storz SE & Co. KG, B Braun Melsungen AG, Baxter International Inc, ConvaTec Group Plc and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Urethral Slings segment has the highest revenue of US $303.37 million and is expected to grow at CAGR of 5.38% by 2027 Urethral Slings segment has highest cagr growth of 5.38%.

Urethral Slings

Urethral Slings segment was valued at US $269.63 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $432.09 million by 2027. Urethral Slings segment represented US $33.74 million opportunity over 2019-2021 and estimated to create US $128.73 million opportunity in 2027 over 2021.

Electrical Stimulation Devices

Electrical Stimulation Devices segment was valued at US $163.61 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $262.19 million by 2027. Electrical Stimulation Devices segment represented US $20.47 million opportunity over 2019-2021 and estimated to create US $78.11 million opportunity in 2027 over 2021.

Artificial Urinary Sphincters

Artificial Urinary Sphincters segment was valued at US $141.61 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $226.93 million by 2027. Artificial Urinary Sphincters segment represented US $17.72 million opportunity over 2019-2021 and estimated to create US $67.61 million opportunity in 2027 over 2021.

Catheters and Others

Catheters and Others segment was valued at US $40.21 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $64.44 million by 2027. Catheters and Others segment represented US $5.03 million opportunity over 2019-2021 and estimated to create US $19.20 million opportunity in 2027 over 2021.

End-User

Introduction

In 2021, Hospitals segment has the highest revenue of US $290.86 million and is expected to grow at CAGR of 5.38% by 2027 Other End-Users segment has highest cagr growth of 5.38%.

Hospitals

Hospitals segment was valued at US $258.52 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $414.29 million by 2027. Hospitals segment represented US $32.35 million opportunity over 2019-2021 and estimated to create US $123.42 million opportunity in 2027 over 2021.

Ambulatory Surgical Centres

Ambulatory Surgical Centres segment was valued at US $183.01 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $293.28 million by 2027. Ambulatory Surgical Centres segment represented US $22.90 million opportunity over 2019-2021 and estimated to create US $87.37 million opportunity in 2027 over 2021.

Other End-Users

Other End-Users segment was valued at US $173.53 million in 2019 and is projected to grow at 5.38% CAGR over the forecast period to reach US $278.09 million by 2027. Other End-Users segment represented US $21.71 million opportunity over 2019-2021 and estimated to create US $82.85 million opportunity in 2027 over 2021.